A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer - Regional Cancer Care Associates LLC

Clinical Trials

A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Type of Cancer
Breast Oncology
Locations
Hackensack
Sponsor
Alliance Foundation
Protocol Number
AFT-05 PrECOG0109 PALLAS
Cancer Diagnosis
To Learn More Call
201-510-0910